Zydus Lifesciences Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

Zydus Lifesciences' board has approved the financial results for the quarter ended June 30, 2025. The company reported consolidated revenue from operations of ₹6,573.7 Cr and a net profit of ₹1,466.8 Cr for the quarter. Basic EPS stood at ₹14.58.

A major strategic update is the completion of an 85.6% stake acquisition in Amplitude Surgical SA, France, on July 29, 2025. Zydus's subsidiary has launched a tender offer for the remaining shares at €6.25 each, with plans to fully acquire and delist Amplitude.